270 related articles for article (PubMed ID: 30244877)
1. Circulating Tumor Cell Assessment in Presumed Early Stage Non-Small Cell Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy: A Prospective Pilot Study.
Frick MA; Kao GD; Aguarin L; Chinniah C; Swisher-McClure S; Berman AT; Levin WP; Cengel KA; DeCesaris C; Hahn SM; Dorsey JF; Simone CB
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(3):536-542. PubMed ID: 30244877
[TBL] [Abstract][Full Text] [Related]
2. Circulating Tumor Cells Are Associated with Recurrent Disease in Patients with Early-Stage Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiotherapy.
Frick MA; Feigenberg SJ; Jean-Baptiste SR; Aguarin LA; Mendes A; Chinniah C; Swisher-McClure S; Berman A; Levin W; Cengel KA; Hahn SM; Dorsey JF; Simone CB; Kao GD
Clin Cancer Res; 2020 May; 26(10):2372-2380. PubMed ID: 31969332
[TBL] [Abstract][Full Text] [Related]
3. Early Detection of Recurrence in Patients With Locally Advanced Non-Small-Cell Lung Cancer via Circulating Tumor Cell Analysis.
Chinniah C; Aguarin L; Cheng P; Decesaris C; Cutillo A; Berman AT; Frick M; Doucette A; Cengel KA; Levin W; Hahn S; Dorsey JF; Simone CB; Kao GD
Clin Lung Cancer; 2019 Sep; 20(5):384-390.e2. PubMed ID: 31221522
[TBL] [Abstract][Full Text] [Related]
4. Tracking viable circulating tumor cells (CTCs) in the peripheral blood of non-small cell lung cancer (NSCLC) patients undergoing definitive radiation therapy: pilot study results.
Dorsey JF; Kao GD; MacArthur KM; Ju M; Steinmetz D; Wileyto EP; Simone CB; Hahn SM
Cancer; 2015 Jan; 121(1):139-49. PubMed ID: 25241991
[TBL] [Abstract][Full Text] [Related]
5. Multiblock Discriminant Analysis of Integrative
Lee SH; Kao GD; Feigenberg SJ; Dorsey JF; Frick MA; Jean-Baptiste S; Uche CZ; Cengel KA; Levin WP; Berman AT; Aggarwal C; Fan Y; Xiao Y
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1451-1465. PubMed ID: 33662459
[TBL] [Abstract][Full Text] [Related]
6. Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation.
Repka MC; Aghdam N; Kataria SK; Campbell L; Suy S; Collins SP; Anderson E; Lischalk JW; Collins BT
Radiat Oncol; 2017 Oct; 12(1):162. PubMed ID: 29052514
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC).
von Reibnitz D; Shaikh F; Wu AJ; Treharne GC; Dick-Godfrey R; Foster A; Woo KM; Shi W; Zhang Z; Din SU; Gelblum DY; Yorke ED; Rosenzweig KE; Rimner A
Acta Oncol; 2018 Nov; 57(11):1567-1573. PubMed ID: 29873277
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Single- and Three-fraction Schedules of Stereotactic Body Radiation Therapy for Peripheral Early-stage Non-Small-cell Lung Cancer.
Ma SJ; Serra LM; Syed YA; Hermann GM; Gomez-Suescun JA; Singh AK
Clin Lung Cancer; 2018 Mar; 19(2):e235-e240. PubMed ID: 29153897
[TBL] [Abstract][Full Text] [Related]
9. Three- Versus Five-Fraction Regimens of Stereotactic Body Radiotherapy for Peripheral Early-Stage Non-Small-Cell Lung Cancer: A Two-Institution Propensity Score-Matched Analysis.
Ma SJ; Cummings M; Serra LM; Syed YA; Hermann GM; Chen Y; Milano MT; Singh AK; Gomez-Suescun JA; Singh DP
Clin Lung Cancer; 2018 May; 19(3):e297-e302. PubMed ID: 29254649
[TBL] [Abstract][Full Text] [Related]
10. Repeat stereotactic body radiotherapy (SBRT) for local recurrence of non-small cell lung cancer and lung metastasis after first SBRT.
Ogawa Y; Shibamoto Y; Hashizume C; Kondo T; Iwata H; Tomita N; Ogino H
Radiat Oncol; 2018 Jul; 13(1):136. PubMed ID: 30055636
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiation therapy and intensity modulated radiation therapy induce different plasmatic cytokine changes in non-small cell lung cancer patients: a pilot study.
Trovo M; Giaj-Levra N; Furlan C; Bortolin MT; Muraro E; Polesel J; Minatel E; Tedeschi R; Filippi AR; Alongi F; Ricardi U
Clin Transl Oncol; 2016 Oct; 18(10):1003-10. PubMed ID: 26687367
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: an updated retrospective study on local failure and survival rates.
Jeppesen SS; Schytte T; Jensen HR; Brink C; Hansen O
Acta Oncol; 2013 Oct; 52(7):1552-8. PubMed ID: 23902274
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Retrospective, Single-Center Study of 55 Patients.
Bhandari RP; Stanford JD; Packianathan S; Duggar WN; Kanakamedala MR; Zhang X; Giri SP; Kumar PP; Harrell LM; Mangana SH; Yang C; Vijayakumar S
Oncology; 2016; 91(4):194-204. PubMed ID: 27427761
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer.
Nantavithya C; Gomez DR; Wei X; Komaki R; Liao Z; Lin SH; Jeter M; Nguyen QN; Li H; Zhang X; Poenisch F; Zhu XR; Balter PA; Feng L; Choi NC; Mohan R; Chang JY
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):558-563. PubMed ID: 29680255
[TBL] [Abstract][Full Text] [Related]
15. Recurrence Patterns and Second Primary Lung Cancers After Stereotactic Body Radiation Therapy for Early-Stage Non-Small-Cell Lung Cancer: Implications for Surveillance.
Spratt DE; Wu AJ; Adeseye V; Din SU; Shaikh F; Woo KM; Zhang Z; Foster A; Rosenzweig KE; Gewanter R; Huang J; Rimner A
Clin Lung Cancer; 2016 May; 17(3):177-183.e2. PubMed ID: 26602271
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial.
Timmerman RD; Paulus R; Pass HI; Gore EM; Edelman MJ; Galvin J; Straube WL; Nedzi LA; McGarry RC; Robinson CG; Schiff PB; Chang G; Loo BW; Bradley JD; Choy H
JAMA Oncol; 2018 Sep; 4(9):1263-1266. PubMed ID: 29852037
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Single- and Five-fraction Regimens of Stereotactic Body Radiation Therapy for Peripheral Early-stage Non-small-cell Lung Cancer: A Two-institution Propensity-matched Analysis.
Cummings MA; Ma SJ; Hermann G; Serra L; Syed Y; Malhotra HK; Chen Y; Milano MT; Gomez-Suescun JA; Singh DP; Singh AK
Clin Lung Cancer; 2018 Nov; 19(6):511-517. PubMed ID: 30131257
[TBL] [Abstract][Full Text] [Related]
18. Integration of Deep Learning Radiomics and Counts of Circulating Tumor Cells Improves Prediction of Outcomes of Early Stage NSCLC Patients Treated With Stereotactic Body Radiation Therapy.
Jiao Z; Li H; Xiao Y; Dorsey J; Simone CB; Feigenberg S; Kao G; Fan Y
Int J Radiat Oncol Biol Phys; 2022 Mar; 112(4):1045-1054. PubMed ID: 34775000
[TBL] [Abstract][Full Text] [Related]
19. Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology.
Wendel M; Bazhenova L; Boshuizen R; Kolatkar A; Honnatti M; Cho EH; Marrinucci D; Sandhu A; Perricone A; Thistlethwaite P; Bethel K; Nieva J; Heuvel Mv; Kuhn P
Phys Biol; 2012 Feb; 9(1):016005. PubMed ID: 22307026
[TBL] [Abstract][Full Text] [Related]
20. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
Zhou J; Dong F; Cui F; Xu R; Tang X
Cancer Chemother Pharmacol; 2017 Apr; 79(4):825-833. PubMed ID: 28289866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
